We modelled 10-year risk of cirrhosis/HCC across a range of thresholds using competing risk survival analysis and compared their prognostic value using decision curve analysis (DCA).<h4>Results</h4>Blood tests enabling calculation of FIB-4, APRI and AST/ALT were available for 203,005 people. The gene discussed is GPT; the disease is hepatocellular carcinoma.